| abstract |
The present disclosure includes compositions that target minor histocompatibility (H) antigen (HA-1H?), For example, to prevent or manage hematologic malignancy recurrence after allogeneic hematopoietic stem cell transplantation (HCT) and Provide a method. Also provided are transgene constructs that encode engineered binding proteins, such as T cell receptors or chimeric antigen receptors, and optionally further components, such as co-receptors and / or safety switches. Such transgene constructs can transduce immune cells, such as T cells, in subjects with hematologic malignancies or at risk of relapse of hematological malignancies (eg, leukemia, lymphoma, myeloma) Can be used as an immunotherapy. [Selection] Figure 30 |